Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations
about
Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysisUse of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISADetection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional surveyIncidence of herpes simplex virus type 2 infections in Africa: a systematic reviewEarlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural MalawiCluster randomized evaluation of Adolescent Girls Empowerment Programme (AGEP): study protocol.HIV prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya.Performance of HSV-2 type specific serological tests in men in Kenya.Diagnosis of genital herpes simplex virus infection in the clinical laboratoryHerpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing.Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population.Assessing the validity of sexual behaviour reports in a whole population survey in rural Malawi.Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.Decline in HIV prevalence among young men in the general population of Cotonou, Benin, 1998-2008.Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, Western Kenya, 1997 and 2008.Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory.Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban UgandansMature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts.Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countriesPrevalence, incidence and determinants of herpes simplex virus type 2 infection among HIV-seronegative women at high-risk of HIV infection: a prospective study in Beira, Mozambique.Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV.Evaluating HIV Prevention Programs: Herpes Simplex Virus Type 2 Antibodies as Biomarker for Sexual Risk Behavior in Young Adults in Resource-Poor Countries.Performance of the Euroline Western blot assay in the detection of herpes simplex virus type 2 antibody in Uganda, China and the USA.Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessmentGlobal Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins.Diagnostics for Developing Countries.Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam.Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso.Herpes simplex virus type 2: epidemiology and management options in developing countries.Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda.Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2.Comparison of three commercial immunoassays for detection of herpes simplex virus type 2 antibodies in commercial sex workers in Yunnan Province, China.Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern MalawiSerologic screening for herpes simplex virus type 2 in persons with human immunodeficiency virus.Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial.Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies.On Estimating Diagnostic Accuracy From Studies With Multiple Raters and Partial Gold Standard EvaluationUse of HIV and HSV-2 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches.Herpes simplex virus type 2 infection as a biomarker for sexual debut among young people in sub-Saharan Africa: a literature review.
P2860
Q24642232-77C51689-C34D-48AC-B5B9-BA68B05AB178Q24812650-5060D698-3D91-4AB1-9DDF-E4D5DF441908Q24816175-934F9B34-97A5-4448-9433-F90DBBCC4229Q27690876-1A419425-4AE3-4834-89FA-57BC5AD83DD3Q28660139-91C51A68-AB8B-4287-9B1E-821E9A83E7F6Q29994820-6D0EDAE5-0D6A-45A7-88F2-31930BAFB77CQ33489508-D41DECDE-93C6-4B76-9DE1-26B2C21758CEQ33646202-BF12EF96-CDAB-4D0D-AD53-A1B6BBD4A0A1Q33655295-A3E8C470-3239-4166-8E5F-01B7D0F28161Q33801040-382E7CFB-7E8F-4180-8D39-71D485E8076EQ33835357-9551114A-118B-4D01-9D29-2F559DDC11E3Q33983486-929DB149-44D0-45AF-B160-CC4B3066D51FQ34019508-8561DC59-2C68-4DF4-9FC4-6F37DA6ED738Q34405632-9F4D92AB-4238-47FE-8A73-9D7D7875170EQ34571479-E35FE5C0-6152-4AB1-B2F7-8F345C121AD2Q34615201-54AE53CC-5502-44C3-907A-075BA668FE09Q34670442-B031C08B-CF29-4909-AB8B-F47059B985CDQ34720324-C3891C4F-61E0-4D66-91F1-85C6573A3751Q34734012-338D4D9E-E29B-40F9-BEAE-C3861FC6613CQ35107935-5476C3FE-5633-4121-B982-9676BB35EFF8Q35138634-A7D6D909-2357-4DB1-B8D7-26DC69346C7DQ35209414-C073DF0C-CD08-4542-91A3-09DA17902B39Q35641538-7938B747-DF25-48F1-8794-059E05099AF1Q35683057-BF24CB26-346A-48E2-898E-78AE68E903CBQ35794339-BC5B166B-FE01-4A76-AF64-EB9DF7055068Q35914319-B215E43F-77A8-4B13-80EC-6E9864345C9EQ36335270-BD54DB71-70E8-431B-BF79-66EAC7B68F4CQ36452397-0A5E4DC3-3C44-448A-AC80-C7B9F6F61F9FQ36612102-0A053212-EDAF-40D7-B180-8C9F5CC07C2CQ36650973-9195FD59-B776-46EA-9280-8DC1E78EC225Q36672554-CAF50216-B824-4819-BA04-0314DD8550C2Q36747513-D2C01660-CB03-4770-B377-307B15A3F293Q36844905-3B305415-85CB-4C64-BFB4-682D369557C0Q36934645-65A78509-FC35-4833-8684-2B5C63EF02C1Q37045917-14007C53-991D-4E2A-AD7E-914779A3CFCAQ37098120-483D4B3E-ED1A-4060-8E62-C1D3BAB91387Q37136326-D27BEB35-5FC1-4A59-9552-EB39591DDE40Q37370798-EF12450F-2713-45D2-8838-20FF2970B38FQ37717863-6AAC0E10-946F-425C-8875-51774588DE30Q38060100-BF40A562-6F2B-46A0-8AAA-4072EE189002
P2860
Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Performance of commercially av ...... type 2 in African populations
@ast
Performance of commercially av ...... type 2 in African populations
@en
type
label
Performance of commercially av ...... type 2 in African populations
@ast
Performance of commercially av ...... type 2 in African populations
@en
prefLabel
Performance of commercially av ...... type 2 in African populations
@ast
Performance of commercially av ...... type 2 in African populations
@en
P2093
P2860
P1476
Performance of commercially av ...... type 2 in African populations
@en
P2093
Bénédicte De Deken
David W G Brown
Eddy van Dyck
Helen A Weiss
John Parry
Judith R Glynn
P2860
P304
P356
10.1128/JCM.42.7.2961-2965.2004
P407
P577
2004-07-01T00:00:00Z